{
  "abstract": "Background Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease predominantly affecting women, carrying significant risks of cirrhosis and liver failure. While ursodeoxycholic acid (UDCA) is the established treatment of choice, overall survival and long-term treatment outcomes in Thai PBC patients remain largely unstudied. This 10-year retrospective cohort study aimed to determine the overall survival and treatment response rates in an HBV-endemic region cohort.Methods We included 57 PBC patients with complete data who were followed at Srinagarind Hospital, Khon Kaen University (2014–2024). Diagnosis required fulfilling at least two standard criteria (biochemical cholestasis, autoantibodies positive, or histology). The primary outcome was 10-year overall survival (OS); secondary outcomes evaluated UDCA treatment response using the Paris I, Paris II, and Rotterdam criteria, and survival differences based on UDCA dosage.Results The cohort was predominantly female (80.7%) with a median age of 55.14 years at diagnosis. Cirrhosis was present in 31.6% at baseline. The 10-year overall survival rate was high at 85.96%. UDCA response rates ranged from 52.63% (Paris II) to 77.19% (Paris I). Overall survival was significantly higher in UDCA responders across all criteria, Paris I: p=0.0038 ( IDDF2026-ABS-0146 Figure 1. Overall Survival Stratified by Paris I Criteria Treatment Response); Paris II: p=0.00088 (IDDF2026-ABS-0146 Figure 2. Overall Survival Stratified by Paris II Criteria Treatment Response); Rotterdam: p<0.0001(IDDF2026-ABS-0146 Figure 3. Overall Survival Stratified by Rotterdam Criteria Treatment Response). While UDCA over-optimal dosing (>15 mg/kg/day) showed a trend towards higher survival, this difference did not reach statistical significance (p=0.077) (IDDF2026-ABS-0146 Figure 4. Overall Survival According to Ursodeoxycholic Acid (UDCA) Dosage).Conclusions Achieving a biochemical response to UDCA is a strong and reliable predictor of improved overall survival in Thai PBC patients. These findings confirm favorable long-term outcomes in this population and highlight that further investigation into the optimal UDCA dosing strategy is warranted.Abstract IDDF2026-ABS-0146 Figure 1Abstract IDDF2026-ABS-0146 Figure 2Abstract IDDF2026-ABS-0146 Figure 3Abstract IDDF2026-ABS-0146 Figure 4",
  "authors": [
    {
      "affiliations": [
        "Department of Medicine, Khon Kaen University, Thailand"
      ],
      "name": "Shunyapat Sirirattanakorn"
    },
    {
      "affiliations": [
        "Division of Gastroenterology and Hepatology, Department of Medicine, Khon Kaen University, Thailand"
      ],
      "name": "Tanita Suttichaimongkol"
    },
    {
      "affiliations": [
        "Department of Medicine, Khon Kaen University, Thailand"
      ],
      "name": "Wisarut Manasirirak"
    },
    {
      "affiliations": [
        "Division of Gastroenterology and Hepatology, Department of Medicine, Khon Kaen University, Thailand"
      ],
      "name": "Kookwan Sawadpanich"
    },
    {
      "affiliations": [
        "Division of Gastroenterology and Hepatology, Department of Medicine, Khon Kaen University, Thailand"
      ],
      "name": "Apichat Sangchan"
    },
    {
      "affiliations": [
        "Division of Gastroenterology and Hepatology, Department of Medicine, Khon Kaen University, Thailand"
      ],
      "name": "Pisaln Mairiang"
    },
    {
      "affiliations": [
        "Division of Gastroenterology and Hepatology, Department of Medicine, Khon Kaen University, Thailand"
      ],
      "name": "Wattana Sukeepaisarnjareon"
    },
    {
      "affiliations": [
        "Division of Gastroenterology and Hepatology, Department of Medicine, Khon Kaen University, Thailand"
      ],
      "name": "Chitchai Rattananukrom"
    }
  ],
  "title": "IDDF2026-ABS-0146 A 10-year cohort study of the overall survival and treatment outcomes in patients with primary biliary cholangitis a single-centered retrospective cohort study",
  "uid": "30f41550-88a4-52b8-bc8d-297a64f9854c"
}